IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?

Valuation Watch: an analysis of pre-money step ups for the 2003-04 biotech IPO window demonstrates that public investors are favoring companies in some therapeutic areas over companies in other areas. CNS and jump-start technologies, for example, are doing well.

The average pre-money IPO step up for US biotech companies that have hit the public markets in this last financing window is 2.11. We've pointed out in this space that biotech investors are saving their money for companies with Phase III products—the only development stage which peaks above this modest average, at 2.60 (see "Biotech Investors: Believing the Dream, Rewarding Phase III IPOs," START-UP, November 2004 Also see "Biotech Investors: Believing the Dream, Rewarding Phase III IPOs" - Scrip, 1 November, 2004.).

But not all Phase III products are alike, and an analysis of these same companies suggests that investors prefer certain...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.